Enanta Pharmaceuticals, Inc. to Post Q3 2024 Earnings of ($1.60) Per Share, Leerink Partnrs Forecasts (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at Leerink Partnrs decreased their Q3 2024 EPS estimates for Enanta Pharmaceuticals in a research note issued on Monday, May 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn ($1.60) per share for the quarter, down from their prior forecast of ($1.46). The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.90) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals’ Q4 2024 earnings at ($1.38) EPS, FY2024 earnings at ($6.04) EPS, FY2025 earnings at ($4.70) EPS, FY2026 earnings at ($3.15) EPS and FY2027 earnings at ($1.55) EPS.

Several other research analysts have also commented on ENTA. HC Wainwright lowered their price target on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. JMP Securities lowered their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a report on Tuesday. Finally, JPMorgan Chase & Co. lowered their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.00.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $12.93 on Thursday. The company has a market capitalization of $273.55 million, a PE ratio of -2.07 and a beta of 0.54. Enanta Pharmaceuticals has a fifty-two week low of $8.08 and a fifty-two week high of $28.25. The firm has a 50 day moving average price of $14.85 and a 200 day moving average price of $12.09.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The company had revenue of $18.00 million during the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its position in Enanta Pharmaceuticals by 417.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,281 shares in the last quarter. Clearstead Advisors LLC acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at about $57,000. Quantbot Technologies LP raised its position in Enanta Pharmaceuticals by 2,300.0% in the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,900 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at about $113,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Enanta Pharmaceuticals in the 1st quarter valued at about $118,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.